Open Market Transactions (Officer)

VERI MEDTECH (VRHI) Announces Officer Purchases: 5,660 Additional Shares of VRHI Stock in Open Market Transactions

NEW YORK, October 2, 2025 - OTC Markets -- Veri Medtech Holdings, Inc. (Stock Ticker Symbol: “VRHI”) ("Veri Medtech"), healthcare technology platform, announced today that via open market transactions:  Sam Adetunji, CEO, completed the additional purchase of 5,660 shares of VRHI stock at an average price per share of $1.45 for an aggregate total of 14,410 VRHI shares repurchased by Mr. Adetunji.  As a result of these purchases, Mr. Adetunji beneficially owns: 7,650,545 shares of VRHI stock. 

“Veri Medtech (VRHI) recently completed comprehensive PCAOB audits for fiscal years 2024 and 2023. This key accomplishment is a critical step in the company’s previously announced strategic focus, plans, and active efforts to seek uplisting to a senior stock exchange, which the company anticipates will help to further market leadership, buttress accretive acquisitions in healthcare technology and accelerate expansion of VRHI’s investor/shareholder base worldwide.  There is more news to come,” said Sam Adetunji, CEO, Veri Medtech (VRHI).

About Veri Medtech (OTC Markets: VRHI): Veri Medtech is a publicly-traded healthcare technology company that offers alternative medicine, personalized diagnostics, and wellness medication on demand. The company leverages telehealth infrastructure, diagnostic intelligence, and scalable digital systems to meet the growing demand for accessible, stigma-free healthcare. Strategically positioned for growth, Veri MedTech actively explores acquisitions that complement its core capabilities and enhance patient engagement across emerging sectors of alternative medicine, longevity, and wellness science. With a strong integration and operational efficiency track record, the company drives accelerated revenue through the continuous generation of high-value patient databases and recurring service models. With a commitment to innovation and patient-centric care, Veri MedTech continues to expand its services and reach, aiming to make personalized healthcare more accessible and effective for all. For more information, please visit: www.VeriMedTech.com

About Veriheal: Veriheal, a wholly-owned subsidiary of publicly-traded Veri Medtech Holdings - OTC Markets (“VRHI”) is a healthcare technology company on a mission to help real people get real medicine.  For more information, please visit: www.Veriheal.com

About DosePop: DosePop, a wholly-owned subsidiary of publicly-traded Veri Medtech Holdings - OTC Markets (“VRHI”), provides a one-stop healthcare technology platform for mental and physical health, all designed to empower you to take charge of your well-being. From weight loss solutions to anti-aging, our treatments are backed by science and administered by licensed professionals. For more information, please visit: www.DosePop.com

About Global Telemedicine:  The global telemedicine market size was valued at USD 114.98 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 17.96% from 2024 to 2030.  Telemedicine market growth is being driven by factors such as consolidation across industry, strategic initiatives by key companies, and increasing healthcare consumerism. Furthermore, rising adoption of telemedicine by providers, increasing patient acceptance and consumer demand, and delivery of improved quality of care are expected to contribute to the growth of the telemedicine market over the forecast period. For instance, in May 2021, Walmart Inc. acquired a telehealth company, MeMD. This acquisition is expected to enable Walmart to expand its offerings and provide virtual access to primary, urgent, and behavioral healthcare services nationwide. Source: Grandview Research. https://www.grandviewresearch.com/industry-analysis/telemedicine-industry

Forward Looking Statements: Cautionary Note Regarding Forward-Looking Statements: This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Veri Medtech (OTC: "VRHI") and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.